Healthcare, Industrials, Financials Jan 04, 2022 08:48 AM (GMT+8) · EqualOcean
Financial Associated Press, January 4 - cornerstone pharmaceutical announced on the Hong Kong stock exchange that the clinical trial application of loratinib (formerly known as loratinib) for cros oncogene 1 ("ros1") positive advanced non-small cell lung cancer ("NSCLC") has been approved by the State Food and Drug Administration of China. This is the world's first key study of loratinib in the treatment of ros1 positive NSCLC.
Related companies: